Mani Foroohar
Stock Analyst at Leerink Partners
(2.45)
# 2,426
Out of 5,152 analysts
171
Total ratings
51.04%
Success rate
-1.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Outperform | $27 → $29 | $13.15 | +120.53% | 5 | Mar 3, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $102 → $104 | $75.16 | +38.37% | 17 | Mar 3, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $120 → $118 | $87.84 | +34.34% | 12 | Feb 26, 2026 | |
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $8.72 | +129.36% | 11 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $66.17 | +29.97% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $320.51 | +9.51% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $53.83 | -66.56% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $6.77 | +195.42% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $4.64 | +50.86% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $16.23 | -38.39% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $3.54 | +69.49% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $27 | $8.64 | +212.50% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $22.13 | +225.35% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $4.59 | +270.37% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $13.20 | +66.67% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $10.60 | +22.64% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $13.03 | +122.56% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $8.71 | +255.91% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.82 | +754.39% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $63.60 | -37.11% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $1.90 | +269.39% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $25.52 | +201.72% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.87 | +23.20% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $57.33 | +32.57% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.71 | +1,888.30% | 4 | May 12, 2022 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Outperform
Price Target: $27 → $29
Current: $13.15
Upside: +120.53%
Ionis Pharmaceuticals
Mar 3, 2026
Maintains: Outperform
Price Target: $102 → $104
Current: $75.16
Upside: +38.37%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Outperform
Price Target: $120 → $118
Current: $87.84
Upside: +34.34%
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $8.72
Upside: +129.36%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $66.17
Upside: +29.97%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $320.51
Upside: +9.51%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $53.83
Upside: -66.56%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $6.77
Upside: +195.42%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $4.64
Upside: +50.86%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $16.23
Upside: -38.39%
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $3.54
Upside: +69.49%
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $8.64
Upside: +212.50%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $22.13
Upside: +225.35%
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $4.59
Upside: +270.37%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $13.20
Upside: +66.67%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $10.60
Upside: +22.64%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $13.03
Upside: +122.56%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $8.71
Upside: +255.91%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.82
Upside: +754.39%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $63.60
Upside: -37.11%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $1.90
Upside: +269.39%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $25.52
Upside: +201.72%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.87
Upside: +23.20%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $57.33
Upside: +32.57%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.71
Upside: +1,888.30%